Long-term cause-specific mortality of patients treated for Hodgkin's disease.

PURPOSE To assess long-term cause-specific mortality of young Hodgkin's disease (HD) patients. PATIENTS AND METHODS The study population consisted of 1,261 patients treated for HD before age 41 between 1965 and 1987. Follow-up was complete until October 2000. For 95% of deaths, the cause was known. Long-term cause-specific mortality was compared with general population rates to assess relative risk (RR) and absolute excess risk (AER) of death. RESULTS After a median follow-up of 17.8 years, 534 patients had died (55% of HD). The RR of death from all causes other than HD was 6.8 times that of the general population, and still amounted to 5.1 after more than 30 years. RRs of death resulting from solid tumors (STs) and cardiovascular disease (CVD) were increased overall (RR = 6.6 and 6.3, respectively), but especially in patients treated before age 21 (RR = 14.8 and 13.6, respectively). When these patients grew older, this elevated mortality decreased. The overall AER of death from causes other than HD increased throughout follow-up. Patients receiving salvage chemotherapy had a significantly increased RR of death from STs, compared to patients receiving initial therapy only. CONCLUSION The main cause of death among HD patients was lymphoma, but after 20 years, HD mortality was negligible. The RRs and AERs of death from second primary cancers (SCs) and CVDs continued to increase after 10 years. Even more than 30 years after diagnosis, HD patients experienced elevated risk of death from all causes other than HD. Increased risk of death from SCs and CVDs was found especially in patients treated before age 21, but these risks seemed to abate with age.

[1]  P. Davis,et al.  Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Stovall,et al.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Neuberg,et al.  Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Friedberg,et al.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.

[6]  R. Greil,et al.  Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Masala,et al.  The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. , 2001, International journal of radiation oncology, biology, physics.

[8]  M. Williams,et al.  Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Aeppli,et al.  The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. , 2000, International journal of radiation oncology, biology, physics.

[10]  P. Goss,et al.  Breast cancer risk following irradiation for Hodgkin's disease. , 2000, Cancer treatment reviews.

[11]  H. Storm,et al.  Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Berger,et al.  Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial. , 2000, Blood.

[13]  D. Neuberg,et al.  Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Lister,et al.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Alvarado,et al.  Second Lethal Events Associated with Treatment for Hodgkin's Disease: A Review of 2980 Patients Treated in a Single Mexican Institute , 2000, Leukemia & lymphoma.

[17]  V. Diehl,et al.  Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R Peto,et al.  Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Noordijk Radiotherapy in early stage Hodgkin's disease: principles and results of recent clinical trials. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  P. Goss,et al.  Current perspectives on radiation-induced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Connors,et al.  Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Willett,et al.  High risk of breast carcinoma after irradiation of young women with Hodgkin's disease , 1997, Cancer.

[23]  S. Hancock,et al.  Gastrointestinal cancer after treatment of Hodgkin's disease. , 1997, International journal of radiation oncology, biology, physics.

[24]  J. Raemaekers,et al.  Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Cu , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  A. Horwich,et al.  Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. , 1997, British Journal of Cancer.

[26]  Hancock,et al.  Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease. , 1996, Seminars in radiation oncology.

[27]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[28]  M. Siimes,et al.  Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. , 1996, European journal of cancer.

[29]  N. Willich,et al.  Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. , 1996, International journal of radiation oncology, biology, physics.

[30]  A. Hagenbeek,et al.  Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. , 1995, Journal of the National Cancer Institute.

[31]  L. Kalish,et al.  Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. , 1995, The cancer journal from Scientific American.

[32]  M. Hudson,et al.  Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Miller,et al.  Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study , 1994, Annals of Internal Medicine.

[34]  A. Hagenbeek,et al.  Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Hagenbeek,et al.  Second cancer risk following Hodgkin's disease: a 20-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Hagenbeek,et al.  A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  U. Tirelli,et al.  Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  D. Linch,et al.  Late mortality in young BNLI patients cured of Hodgkin's disease. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  K. Maclennan,et al.  Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. , 1993, British Journal of Cancer.

[40]  S L Hancock,et al.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.

[41]  J. Lubin,et al.  Coronary artery disease mortality in patients treated for hodgkin's disease , 2010, Cancer.

[42]  P. Steinherz,et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.

[43]  J. Cosset,et al.  Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience , 1991 .

[44]  E. Noordijk,et al.  Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. , 1990, International journal of radiation oncology, biology, physics.

[45]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[46]  B. Hancock,et al.  Immunity in Hodgkin's disease: status after 10 years remission. , 1982, British Journal of Cancer.

[47]  S. Hancock,et al.  Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. , 1988, Annals of internal medicine.

[48]  P. Mazza,et al.  Treatment‐related leukemia in Hodgkin's disease: A multi‐institution study on 75 cases , 1987, Hematological oncology.

[49]  R. Hoover,et al.  Leukemia after therapy with alkylating agents for childhood cancer. , 1987, Journal of the National Cancer Institute.

[50]  J. Boivin,et al.  Coronary heart disease mortality after irradiation for Hodgkin's disease , 1982, Cancer.

[51]  R. Fisher,et al.  Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. , 1980, Annals of internal medicine.

[52]  Z. Fuks,et al.  The long term effects of radiation on T and B lymphocytes in the peripheral blood after regional irradiation , 1977 .